Karyopharm Therapeutics Inc.

DB:25K Stock Report

Market Cap: €80.7m

Karyopharm Therapeutics Valuation

Is 25K undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 25K when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 25K's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 25K's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 25K?

Key metric: As 25K is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 25K. This is calculated by dividing 25K's market cap by their current revenue.
What is 25K's PS Ratio?
PS Ratio0.6x
SalesUS$148.44m
Market CapUS$84.09m

Price to Sales Ratio vs Peers

How does 25K's PS Ratio compare to its peers?

The above table shows the PS ratio for 25K vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.5x
HPHA Heidelberg Pharma
13.6x16.6%€115.6m
MDG1 Medigene
3.1x15.2%€23.0m
2INV 2invest
8.7xn/a€67.3m
CNW co.don
0.7xn/a€6.5m
25K Karyopharm Therapeutics
0.6x22.3%€84.1m

Price-To-Sales vs Peers: 25K is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (8.5x).

Price to Sales Ratio vs Industry

How does 25K's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.8.3x19.6%
25K Karyopharm Therapeutics
 0.6x22.3%US$84.09m
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
25K 0.6xIndustry Avg. 8.3xNo. of Companies5PS0612182430+
6 CompaniesEstimated GrowthMarket Cap
Industry Avg.8.3x34.2%
25K Karyopharm Therapeutics
 0.6x34.4%US$84.09m
No more companies

Price-To-Sales vs Industry: 25K is good value based on its Price-To-Sales Ratio (0.6x) compared to the European Biotechs industry average (8.3x).

Price to Sales Ratio vs Fair Ratio

What is 25K's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

25K PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.6x
Fair PS Ratio2.5x

Price-To-Sales vs Fair Ratio: 25K is good value based on its Price-To-Sales Ratio (0.6x) compared to the estimated Fair Price-To-Sales Ratio (2.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 25K forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.63
€4.37
+590.9%
33.1%€6.80€1.94n/a7
Jan ’26€0.73
€4.12
+461.2%
33.1%€6.41€1.83n/a7
Dec ’25€0.78
€4.12
+427.1%
33.1%€6.41€1.83n/a7
Nov ’25€0.89
€4.01
+352.7%
34.0%€6.44€1.84n/a7
Oct ’25€0.69
€3.99
+475.8%
34.0%€6.41€1.83n/a7
Sep ’25€0.69
€3.99
+480.3%
34.0%€6.41€1.83n/a7
Aug ’25€0.92
€4.73
+416.6%
38.2%€7.47€1.87n/a7
Jul ’25€0.78
€4.73
+503.4%
38.2%€7.47€1.87n/a7
Jun ’25€0.89
€4.84
+441.8%
40.3%€7.42€1.85n/a7
May ’25€1.01
€5.14
+410.6%
35.7%€7.38€2.77n/a7
Apr ’25€1.36
€5.14
+278.0%
35.7%€7.38€2.77n/a7
Mar ’25€1.05
€5.14
+388.5%
35.7%€7.38€2.77n/a7
Feb ’25€0.72
€5.43
+654.2%
37.3%€9.06€2.72n/a8
Jan ’25€0.82
€5.43
+564.6%
37.3%€9.06€2.72€0.738
Dec ’24€0.69
€5.13
+641.9%
40.9%€9.33€2.80€0.7810
Nov ’24€0.80
€6.10
+662.6%
37.8%€9.38€3.75€0.8910
Oct ’24€1.30
€6.10
+370.3%
37.8%€9.38€3.75€0.6910
Sep ’24€1.16
€6.00
+418.1%
36.0%€9.09€3.63€0.6910
Aug ’24€1.64
€6.22
+280.3%
32.0%€9.01€3.61€0.9210
Jul ’24€1.67
€6.53
+291.5%
27.6%€9.07€4.54€0.7810
Jun ’24€2.06
€6.53
+216.8%
27.6%€9.07€4.54€0.8910
May ’24€3.12
€7.85
+151.8%
44.2%€14.60€4.56€1.0110
Apr ’24€3.29
€7.95
+141.6%
45.3%€14.97€4.68€1.3610
Mar ’24€2.80
€7.95
+183.7%
45.3%€14.97€4.68€1.0510
Feb ’24€3.03
€7.91
+160.8%
44.2%€14.72€4.60€0.7210
Jan ’24€2.89
€9.70
+235.3%
41.7%€18.07€5.02€0.829
Analyst Price Target
Consensus Narrative from 7 Analysts
€4.14
Fair Value
84.7% undervalued intrinsic discount
7
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 00:22
End of Day Share Price 2025/01/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Karyopharm Therapeutics Inc. is covered by 19 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Peter LawsonBarclays
Ying HuangBofA Global Research